- Home
- KLRS vs SLGL Comparison
KLRS vs SLGL Comparison
Compare KLRS & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- SLGL
- Stock Information
- Founded
- KLRS 2019
- SLGL 1997
- Country
- KLRS United States
- SLGL Israel
- Employees
- KLRS N/A
- SLGL N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- KLRS Health Care
- SLGL Health Care
- Exchange
- KLRS Nasdaq
- SLGL Nasdaq
- Market Cap
- KLRS 46.0M
- SLGL 49.4M
- IPO Year
- KLRS N/A
- SLGL 2018
- Fundamental
- Price
- KLRS $2.56
- SLGL $23.48
- Analyst Decision
- KLRS Buy
- SLGL Buy
- Analyst Count
- KLRS 1
- SLGL 1
- Target Price
- KLRS N/A
- SLGL $40.00
- AVG Volume (30 Days)
- KLRS 45.1K
- SLGL 30.1K
- Earning Date
- KLRS 08-13-2025
- SLGL 08-15-2025
- Dividend Yield
- KLRS N/A
- SLGL N/A
- EPS Growth
- KLRS N/A
- SLGL N/A
- EPS
- KLRS N/A
- SLGL N/A
- Revenue
- KLRS N/A
- SLGL $23,931,000.00
- Revenue This Year
- KLRS N/A
- SLGL N/A
- Revenue Next Year
- KLRS N/A
- SLGL $31.17
- P/E Ratio
- KLRS N/A
- SLGL N/A
- Revenue Growth
- KLRS N/A
- SLGL 264.86
- 52 Week Low
- KLRS $2.14
- SLGL $4.01
- 52 Week High
- KLRS $24.15
- SLGL $26.89
- Technical
- Relative Strength Index (RSI)
- KLRS 49.38
- SLGL 72.14
- Support Level
- KLRS $2.37
- SLGL $20.06
- Resistance Level
- KLRS $2.58
- SLGL $26.89
- Average True Range (ATR)
- KLRS 0.18
- SLGL 2.57
- MACD
- KLRS 0.01
- SLGL 0.63
- Stochastic Oscillator
- KLRS 64.32
- SLGL 75.10
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.